Latest Integration News

VHM's refreshed feasibility study projects an A$807 million pre-tax NPV for its Goschen rare earths and mineral sands project, with approvals and major procurement work substantially advanced. The project still needs financing, lender due diligence and a Final Investment Decision before construction can begin.

Lightning Minerals says reconnaissance sampling has expanded the Warby Project’s interpreted tungsten system well beyond its World War I-era workings, with rock chips grading up to 5.5% tungsten. The company has fast-tracked further soil sampling to define the anomalies before selecting maiden drill targets.

Telix will acquire ITM in a proposed US$1.65 billion deal that combines a commercial radioisotope supplier with Telix’s precision medicine and therapeutic pipeline. The transaction could give Telix greater supply-chain control and entry into a validated cancer treatment market, but it also brings dilution, integration risk and an unresolved FDA pathway for ITM-11.

BluGlass has begun a three-to-five-month, A$286,000 feasibility collaboration with global photonics company Coherent to develop a novel gallium nitride device for scientific and medical applications. The agreement offers technical and commercial promise, but does not yet include a production commitment or confirmed product launch.

American Tungsten & Antimony has produced antimony ingot from Arizona-mined material at its Nevada refinery, providing the first physical demonstration of its proposed US mine-to-metal chain. The milestone creates samples for testing and customer qualification, but the underlying asset acquisition remains incomplete and product quality is yet to be disclosed.

icetana AI has signed a five-year, $675,480 plus GST Antara Core contract with Millennium Services Group for deployment to one of Australia’s largest retail property groups. The deal is the third Antara Core sale in three months and is expected to add $135,096 to annual recurring revenue from 1 November 2026.

AdAlta says a 10-year, up to US$120 million agreement between manufacturing partner Oribiotech and an undisclosed commercial-stage biopharmaceutical company validates its choice of IRO automation for future cellular immunotherapies. The deal does not create direct revenue for AdAlta, and its lead asset EW-001 will continue with a separate manufacturing process.

MyState delivered a sharp rise in FY26 profit as Auswide integration produced $11.8 million in run-rate synergies, while the group lifted its full-year dividend to 24.5 cents per share. The next test is turning early integration gains into a larger payoff without losing control of technology costs and credit risk.

Acumentis delivered a sharp improvement in profit and cash generation despite lower revenue, supported by cost control and diversification beyond mortgage valuations. The result comes with a governance complication: a Section 249D requisition seeking to replace the chairman and managing director.

Lefroy Exploration is considering folding the high-grade portion of its Burns deposit into the Mt Martin Scoping Study, broadening the development case while pushing delivery into the December quarter. At Lucky Strike, a newly granted licence removes one hurdle but several approvals still stand between the mine and a targeted early 2027 restart.

CurveBeam AI has raised A$1.75 million through an oversubscribed SPP shortfall offer and placement, lifting its recent capital raised to A$7.36 million. The funds will support the HiRise China launch, product development, supply-chain preparation and working capital.

Magnum Mining has completed more than 10,000 metres of drilling at its Piracanjuba North rare earths project in Brazil and is shifting its main effort to the 32.5km² Plateau Zone. A further 2,000-metre diamond drilling phase will run alongside independent resource, radiological and metallurgical studies, although delayed assay turnaround creates a risk to the company’s November timetable.